PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Elranatamab→

Elranatamab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2408850-14-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
BCMA-directed CD3 T-cell-engaging bispecific antibodyantineoplastic biologic
Mechanism of action
Binds B-cell maturation antigen (BCMA) on plasma cells and multiple myeloma cells and CD3 on T cells, bringing T cells into proximity with BCMA-expressing tumour cells and inducing T-cell-mediated cytolysis.
Indications / reported uses
  • Treatment of adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, under the US product indication; current label and local authorisation criteria apply

Sources: US DailyMed — ELREXFIO (elranatamab-bcmm) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Elranatamab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Elranatamab Permitted Daily Exposure (PDE) report (the Elranatamab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Elranatamab Occupational Exposure Limit (OEL) report (the Elranatamab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.